The Patent Finder
AS

AbbVie S.Á.R.L.

First filing 2015
OverviewNotableFeesChangesFamiliesPatent listSources & methods

5 patents currently held

10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2035. from the record

Of the 10 now held by other companies, 6 name AbbVie Global Enterprises Ltd. as their current owner, and 4 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2035
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 27 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2038.
Ends Sep 2038 · High confidence
Also notable
Cited by 25 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Oct 2035 · High confidence
Also notable
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2036.
Ends Jul 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 1, 2027
    The maintenance fee for Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use (US 10,428,017) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
  • 1 fee due Sep 30, 2027
    The maintenance fee for Heteroaryl Substituted Pyridines and Methods of Use (US 10,604,515) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 1 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

PatentTitleStatusExpiresConfidence
US 10,118,916Modulators of Cystic Fibrosis Transmembrane Conductance Regulator Protein
Grace period ended
 · Low confidence
Grace period endedLow confidence
US 10,138,227Heteroaryl Substituted Pyridines and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 10,604,515Heteroaryl Substituted Pyridines and Methods of Use
In force
 · Low confidence
In forceLow confidence
US 9,981,910Substituted Pyrrolidines and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 10,428,017Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 5: 10 patents in force now held by others · 3 patents ended · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited